UroMems Appoints Dan Rose as New Board Chairman to Lead Innovative Medical Device Development

UroMems Welcomes Dan Rose as New Board Chairman

UroMems, a pioneering company in medical technology, is thrilled to announce the appointment of Dan Rose as the new chairman of its board. This significant leadership change comes at a crucial moment as the company gears up for the pivotal clinical trials of its groundbreaking product, UroActive. UroActive is heralded as the first smart automated artificial urinary sphincter that aims to revolutionize the treatment of stress urinary incontinence (SUI).

In the words of UroMems co-founder and CEO Hamid Lamraoui, "We are very pleased to welcome Dan as our new board chair at this very exciting time for the company." Lamraoui emphasizes that Rose's extensive experience and dynamic leadership are vital as UroMems embarks on the next stage of large-scale trials in both the United States and Europe, preparing for imminent commercial launch.

Dan Rose brings a wealth of expertise accumulated over a 25-year career in the medical device sector. Currently, he holds the position of CEO at Endovascular Engineering, a company based in Silicon Valley focused on resolving venous thromboembolism issues. Previously, he served as the CEO of LimFlow S.A., where he adeptly steered the company towards an acquisition by Inari Medical worth up to $415 million. At LimFlow, Rose was instrumental in executing strategies that expanded the company while enhancing its product offerings.

Rose’s track record also includes significant leadership roles at reputable organizations such as Direct Flow Medical, Sequana Medical AG, and Medtronic. His academic credentials include a bachelor’s and master’s degree from the University of Virginia and an MBA from the Darden School of Business, further establishing him as a well-rounded addition to UroMems’ board.

Reflecting on his new role, Rose stated, “I am grateful for the opportunity to move into this position and for the potential to make a real impact on the quality of life for millions suffering from SUI.” His commitment to driving UroMems’ innovative, patient-centered technology forward is evident, acknowledging the strong momentum the company has developed thus far.

UroMems has marked several critical achievements in recent times, including raising an impressive $47 million in funding following successful outcomes from its first multicenter clinical study. Stress urinary incontinence, which affects a staggering 40 million people in the U.S. and about 90 million in Europe, is a condition that can significantly impair quality of life. The implications of SUI often result in serious mental health challenges, including depression and social stigma.

About UroActive

UroActive is at the forefront of UroMems’ technological innovations. It is recognized as the first active implantable electronic artificial urinary sphincter designed to address sphincter insufficiency in both male and female patients. Leveraging a unique mechatronic platform, UroActive integrates smart, digital, and robotic systems to enhance patient experience while optimizing safety and overall performance. Currently, the product is still in the development phase and has yet to receive marketing authorization from the FDA or be made available in the U.S. and Europe.

In conclusion, UroMems is well-poised to make significant strides in advancing medical device technology under Rose's leadership. As the company embarks on this next chapter, it aims not only to innovate but also to transform lives positively by alleviating the burdens associated with stress urinary incontinence. For additional details regarding UroMems and its groundbreaking developments, consider exploring their official website at www.uromems.com.